Paper7366673
Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism.
Shepherd J and 4 others. N Engl J Med, 1980. Cited by 343 papers, by iCite.
Cite this record
ConductScience Library. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. Papers, record 7366673. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7366673
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cholestyramine Resin | Major topic |
| Hyperlipoproteinemia Type II | Major topic |
| Lipoproteins, LDL | Major topic |
| Receptors, Drug | Major topic |
| Adult | |
| Aged | |
| Cholesterol | |
| Heterozygote | |
| Humans | |
| Middle Aged |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00476710 | Effects of Colesevelam HCl On Bile Acid Kinetics | Background | ClinicalTrials.gov | |
| NCT00596427 | Mechanisms of Glucose Lowering Effect of Colesevelam HCl | Background | ClinicalTrials.gov |
Cited by57
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 343 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 27570415 | Mechanisms of triglyceride metabolism in patients with bile acid diarrhea. | World J Gastroenterol | 2016 | https://conductscience.org/library/papers/27570415 | PubMed |
| 26045273 | Impact of Inhibiting Ileal Apical versus Basolateral Bile Acid Transport on Cholesterol Metabolism and Atherosclerosis in Mice. | Dig Dis | 2015 | https://conductscience.org/library/papers/26045273 | PubMed |
| 25628509 | Patient tolerance and acceptance of colesevelam hydrochloride: focus on type-2 diabetes mellitus. | P T | 2015 | https://conductscience.org/library/papers/25628509 | PubMed |
| 25061583 | Dyslipidemia in children and adolescents: when and how to diagnose and treat? | Pediatr Gastroenterol Hepatol Nutr | 2014 | https://conductscience.org/library/papers/25061583 | PubMed |
| 24058856 | The impact of mitochondrial oxidative stress on bile acid-like molecules in C. elegans provides a new perspective on human metabolic diseases. | Worm | 2013 | https://conductscience.org/library/papers/24058856 | PubMed |
| 23754124 | A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. | Drugs | 2013 | https://conductscience.org/library/papers/23754124 | PubMed |
| 23677836 | Challenges in the pharmacologic management of obesity and secondary dyslipidemia in children and adolescents. | Paediatr Drugs | 2013 | https://conductscience.org/library/papers/23677836 | PubMed |
| 22438816 | Mitochondrial oxidative stress alters a pathway in Caenorhabditis elegans strongly resembling that of bile acid biosynthesis and secretion in vertebrates. | PLoS Genet | 2012 | https://conductscience.org/library/papers/22438816 | PubMed |
| 21938413 | Familial hypercholesterolemia: present and future management. | Curr Cardiol Rep | 2011 | https://conductscience.org/library/papers/21938413 | PubMed |
| 19875558 | Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. | Diabetes Care | 2009 | https://conductscience.org/library/papers/19875558 | PubMed |
| 18950282 | Cholesterol-metabolizing cytochromes P450: implications for cholesterol lowering. | Expert Opin Drug Metab Toxicol | 2008 | https://conductscience.org/library/papers/18950282 | PubMed |
| 18633604 | Cytochrome P450 and gene activation--from pharmacology to cholesterol elimination and regression of atherosclerosis. | Eur J Clin Pharmacol | 2008 | https://conductscience.org/library/papers/18633604 | PubMed |
| 17315604 | Optimal lipid modification: the rationale for combination therapy. | Vasc Health Risk Manag | 2005 | https://conductscience.org/library/papers/17315604 | PubMed |
| 15509187 | Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. | Clin Pharmacokinet | 2004 | https://conductscience.org/library/papers/15509187 | PubMed |
| 10529092 | Effects of cholestyramine on hepatic cholesterol 7alpha-hydroxylase and serum 7alpha-hydroxycholesterol in the hamster. | Lipids | 1999 | https://conductscience.org/library/papers/10529092 | PubMed |
| 9046034 | Hypolipidemic action of curcumin, the active principle of turmeric (Curcuma longa) in streptozotocin induced diabetic rats. | Mol Cell Biochem | 1997 | https://conductscience.org/library/papers/9046034 | PubMed |
| 8735642 | Preservation of endothelium-dependent relaxation in cholesterol-fed and streptozotocin-induced diabetic mice by the chronic administration of cholestyramine. | Br J Pharmacol | 1996 | https://conductscience.org/library/papers/8735642 | PubMed |
| 8347487 | Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8347487 | PubMed |
| 8251323 | Hyperlipidemia in childhood nephrotic syndrome. | Pediatr Nephrol | 1993 | https://conductscience.org/library/papers/8251323 | PubMed |
| 7085881 | Significance of low density lipoprotein production in the regulations of plasma cholesterol level in man. | J Clin Invest | 1982 | https://conductscience.org/library/papers/7085881 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7366673
GET https://conductscience.org/api/papers/v1/7366673/cited_by?page=2